TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8755685

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg/d (increased to 40 mg/d if inadequate response)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg + indomethacin 75 mg/d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1389702

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg twice a day
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 3880480

Group type: EXPERIMENTAL
Intervention: Eudragit E 100-coated microcapsules
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ethylcellulose-coated microcapsules
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference tablet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stimulated intestinal fluid with adjusted ionic strength
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Eudragit E 100 polymer
Number of subjects: 20
Study: 28152246

Group type: EXPERIMENTAL
Intervention: IPS e.max CAD (DM group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lava Plus (LM group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metal‐ceramic (MC group)
Number of subjects: 30
Study: 29678772

Group type: EXPERIMENTAL
Intervention: High dose minocycline (200 mg per day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Minocycline (both doses)
Number of subjects: 75
Study: 27126487

Group type: EXPERIMENTAL
Intervention: Integrated PMTCT care package
Number of subjects: 369

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 369
Study: 25159234

Group type: EXPERIMENTAL
Intervention: Intensive glycemic control targeting glycated hemoglobin level of <6.0%
Number of subjects: 10082

Group type: COMPARATOR
Intervention: Standard glycemic control targeting glycated hemoglobin level of 7.0% to 7.9%
Number of subjects: 10082

Group type: EXPERIMENTAL
Intervention: Patients with DM and new-onset AF
Number of subjects: 10082
Study: 22479327

Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 40

Group type: COMPARATOR
Intervention: ABC/3TC
Number of subjects: 40
Study: 20226994

Group type: EXPERIMENTAL
Intervention: EGG breakfast
Number of subjects: 21

Group type: COMPARATOR
Intervention: BAGEL breakfast
Number of subjects: 21
Study: 17899016

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15863797

Group type: EXPERIMENTAL
Intervention: Risperidone (mean modal dose=3.3 mg)
Number of subjects: 555

Group type: COMPARATOR
Intervention: Haloperidol (mean modal dose=2.9 mg)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 555

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 555
Study: 12202661

Group type: EXPERIMENTAL
Intervention: UFT (300 mg/m²/d) and LV (75 or 90 mg/d) for 28 days every 35 days
Number of subjects: 816

Group type: COMPARATOR
Intervention: IV bolus 5-FU (425 mg/m²/d) and LV (20 mg/m²/d) for 5 days every 28 days
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: UFT/LV
Number of subjects: 816

Group type: COMPARATOR
Intervention: 5-FU/LV
Number of subjects: 816
Study: 10599373

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Betamethasone propionate cream alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both therapies combined (hydrocolloid dressing and Betamethasone propionate cream)
Number of subjects: 39
Study: 8942719

Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (saline) injection
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pneumatic dilation
Number of subjects: 16
Study: 2018160

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy with buspirone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cognitive-behavior therapy with placebo
Number of subjects: 94
Study: 7043002

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide
Number of subjects: 38
Study: 31603392

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA)
Number of subjects: 2732

Group type: EXPERIMENTAL
Intervention: Light Physical Activity
Number of subjects: 2732

Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Physical Activity (MVPA)
Number of subjects: 2732

Group type: EXPERIMENTAL
Intervention: Total Physical Activity (PA)
Number of subjects: 2732

Group type: EXPERIMENTAL
Intervention: Physical Inactivity
Number of subjects: 2732

Group type: EXPERIMENTAL
Intervention: Socioeconomic Level
Number of subjects: 2732
Study: 31797855

Group type: EXPERIMENTAL
Intervention: Quirynen's protocol of one‐stage full‐mouth disinfection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bollen's protocol of one‐stage full‐mouth disinfection
Number of subjects: 40
Study: 28338180

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg/kg in 20 ml infused for 10 min)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Dezocine (0.1 mg/kg in 20 ml infused for 10 min)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (20 ml NS infused intravenously 10 min before anesthetic induction)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study: 25652752

Group type: EXPERIMENTAL
Intervention: Active electrode stimulation for 3 months followed by sham stimulation for 3 months (ON-OFF arm)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Sham stimulation for 3 months followed by active stimulation for 3 months (OFF-ON arm)
Number of subjects: 5
Study: 24167370

Group type: EXPERIMENTAL
Intervention: 2-dose series of nonadjuvated monovalent influenza A H1N1 2009 vaccine
Number of subjects: 45
Study: 21161699

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 19527979

Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stents (SES)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 712
Study: 17069486

Group type: EXPERIMENTAL
Intervention: Laser needle irradiation on the right forearm at acupuncture point Pe6
Number of subjects: 33

Group type: COMPARATOR
Intervention: No laser irradiation (Control group)
Number of subjects: 33
Study: 15346229

Group type: EXPERIMENTAL
Intervention: 30 hours of sleep deprivation with intermittent physical exercise (cycling at 50% VO2peak for 20 min every 2 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sedentary activities (control group)
Number of subjects: 6
Study: 12577420

Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza (SM) and Astragalus membranaceus (AM)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 84
Study: 9264433

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 to 80 mg/day)
Number of subjects: 0
Study: 8221271

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (14.4% NaCl)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Methacholine
Number of subjects: 19
Study: 3303978

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) combined with exercise
Number of subjects: 22

Group type: COMPARATOR
Intervention: Exercise alone (Control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Competitive athletes
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Recreational athletes
Number of subjects: 22
Study: 29663363

Group type: EXPERIMENTAL
Intervention: FAM19A4/mir124-2 methylation test
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Cytology test (threshold borderline dyskaryosis or ASCUS)
Number of subjects: 1040
Study: 27959701

Group type: EXPERIMENTAL
Intervention: High-dose crizanlizumab (5.0 mg/kg)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 26041682

Group type: EXPERIMENTAL
Intervention: ESRA‐C intervention delivered via the Internet or tablet at the clinic
Number of subjects: 0

Group type: COMPARATOR
Intervention: ESRA‐C assessment only (control)
Number of subjects: 0
Study: 23915107

Group type: EXPERIMENTAL
Intervention: Invitation letter (n=17,068)
Number of subjects: 31452

Group type: COMPARATOR
Intervention: No invitation letter (Control group, n=14,384)
Number of subjects: 31452

Group type: EXPERIMENTAL
Intervention: Invitation letter effectiveness
Number of subjects: 31452
Study: 21430075

Group type: EXPERIMENTAL
Intervention: 30 mg/d of lycopene as a tomato oleoresin for 21 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo for 21 days
Number of subjects: 105
Study: 18662629

Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 16282635

Group type: EXPERIMENTAL
Intervention: Subject advocate procedures
Number of subjects: 73
Study: 14755152

Group type: EXPERIMENTAL
Intervention: Herbal preparation STW 5‐II
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 11839319

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patient-controlled analgesia
Number of subjects: 0
Study: 9728734

Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: 1.0 mg flunitrazepam
Number of subjects: 1507

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1507
Study: 7994508

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 mg daily to 1.2 mg daily over 14 days)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Dummy medication (placebo)
Number of subjects: 86
Study: 3133964

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Reproterol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate plus reproterol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30586113

Group type: EXPERIMENTAL
Intervention: Short-Duration HIIT (SDHIIT, n = 10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Long-Duration HIIT (LDHIIT, n = 10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 30
Study: 28266963

Group type: EXPERIMENTAL
Intervention: TV-45070 ointment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TV-45070 ointment in patients with R1150W polymorphism
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: TV-45070 ointment in wild-type carriers
Number of subjects: 70
Study: 26556051

Group type: EXPERIMENTAL
Intervention: IVUS-guided everolimus-eluting stent implantation
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Angiography-guided everolimus-eluting stent implantation
Number of subjects: 1400
Study: 23139215

Group type: EXPERIMENTAL
Intervention: Probiotic conditioned media (PCM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis conditioned media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus conditioned media
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tollip siRNA-mediated knockdown
Number of subjects: 0
Study: 22018587

Group type: EXPERIMENTAL
Intervention: Standard non-hydrolysed cows' milk-based formula with a mixture of specific oligosaccharides (prebiotics group)
Number of subjects: 830

Group type: COMPARATOR
Intervention: Similar formula without oligosaccharides (control group)
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Breast-fed infants (reference group)
Number of subjects: 830
Study: 18446122

Group type: EXPERIMENTAL
Intervention: Transthoracic Impedance ratio (TTIr) measured using the Bodystat Dual Scan 2005
Number of subjects: 23

Group type: COMPARATOR
Intervention: Extravascular lung water (EVLW) and index (EVLWI) measured using the PiCCO system
Number of subjects: 23
Study: 18386615

Group type: EXPERIMENTAL
Intervention: Romanian subjects
Number of subjects: 262
Study: 12556015

Group type: EXPERIMENTAL
Intervention: Bronchial asthma patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: Other pulmonary disorder patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Asthmatic males
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Asthmatic females
Number of subjects: 150
Study: 10785225

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Finasteride (5 mg/d)
Number of subjects: 70
Study: 9148355

Group type: EXPERIMENTAL
Intervention: Bair Hugger heater
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 8380765

Group type: EXPERIMENTAL
Intervention: GLA (gamma-linolenic acid) at a dose of 480 mg/day
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 2952426

Group type: EXPERIMENTAL
Intervention: Guar bread (100 g guar/kg wheat flour)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Guar granulate (5 g twice daily providing 8.3 g guar/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control bread
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Guar bread
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Guar granulate
Number of subjects: 16
Study: 29546659

Group type: COMPARATOR
Intervention: Automated adherence alert messages (alert)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Social support (partner)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Both social support and alerts (partner + alert)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 179
Study: 27758120

Group type: EXPERIMENTAL
Intervention: Laser DARRT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bullseye technique
Number of subjects: 20
Study: 24861833

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham moxa devices
Number of subjects: 0
Study: 24458964

Group type: COMPARATOR
Intervention: IRC VAS
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Brimless VAS
Number of subjects: 9
Study: 20734132

Group type: EXPERIMENTAL
Intervention: Multimedia, multimodal exercise program (strength, balance, and endurance training)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Sham flexibility and relaxation program
Number of subjects: 89
Study: 17988889

Group type: EXPERIMENTAL
Intervention: Coronary bypass
Number of subjects: 1054

Group type: COMPARATOR
Intervention: Coronary angioplasty
Number of subjects: 1054
Study: 16173889

Group type: EXPERIMENTAL
Intervention: Shaping condition - $50 vouchers on Wednesday and Friday for meeting quantitative urinalysis criteria and a $100 voucher on the following Monday for meeting qualitative criteria
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terminal condition - only the $100 earning opportunity for meeting the qualitative criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shaping condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terminal condition
Number of subjects: 0
Study: 12771763

Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg orally once a day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg orally once a day) + Tolterodine (2 mg orally twice daily)
Number of subjects: 50
Study: 10852263

Group type: EXPERIMENTAL
Intervention: Improved physical health after 6 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Improved mental health after 6 months
Number of subjects: 90
Study: 8659218

Group type: EXPERIMENTAL
Intervention: Postoperative low molecular weight heparin (tinzaparin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 1894930

Group type: EXPERIMENTAL
Intervention: Edoxudine 3% cream for 5 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 6222710

Group type: EXPERIMENTAL
Intervention: Tobramycin plus Clindamycin (TM/C)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Moxalactam (MOX)
Number of subjects: 100
Study: 31521449

Group type: EXPERIMENTAL
Intervention: Oral melatonin 0.3 mg/kg/8 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral diazepam 1 mg/kg/day divided into three doses
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both melatonin and diazepam
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral melatonin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral diazepam
Number of subjects: 60
Study: 30373644

Group type: EXPERIMENTAL
Intervention: Adherence to the 17-item CONSORT‐A checklist
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: European Journal of Anesthesiology
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Anaesthesia
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Trial design adherence
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Contact of authors (e-mail address)
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Recruitment status
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Number of participants analyzed
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Randomization
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Funding disclosure
Number of subjects: 622
Study: 27457968

Group type: EXPERIMENTAL
Intervention: Liquid fish oil (6 meals/week)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Microencapsulated powder (conventional meals)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (conventional meals and placebo powder)
Number of subjects: 99
Study: 24468081

Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 12
Study: 23207259

Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional TBNA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Liquid‐based cytology
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cell block specimens
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cytopathologists' agreement
Number of subjects: 50
Study: 21034626

Group type: EXPERIMENTAL
Intervention: Anti-oxidants group (vitamin C, vitamin E, Salvia Miltiorrhiza L)
Number of subjects: 4814

Group type: COMPARATOR
Intervention: Control group (no medicine)
Number of subjects: 4814

Group type: EXPERIMENTAL
Intervention: Anti-oxidants group (subgroup analysis)
Number of subjects: 4814

Group type: EXPERIMENTAL
Intervention: Anti-oxidants group (high-risk factors)
Number of subjects: 4814

Group type: COMPARATOR
Intervention: Control group (high-risk factors)
Number of subjects: 4814

Group type: COMPARATOR
Intervention: Control group (specific high-risk factors)
Number of subjects: 4814

Group type: EXPERIMENTAL
Intervention: Anti-oxidants group (specific high-risk factors)
Number of subjects: 4814
Study: 17067720

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (150 microg/mL)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Intravenous morphine (10 mg/mL)
Number of subjects: 67
Study: 15764007

Group type: EXPERIMENTAL
Intervention: Qi-training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (relaxation)
Number of subjects: 18
Study: 12063536

Group type: EXPERIMENTAL
Intervention: Skin prick test (SPT) with raw peanut extract
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Specific IgE assay
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Combined use of SPT and specific IgE assay
Number of subjects: 363

Group type: COMPARATOR
Intervention: DBPCFC (Double-blind, placebo-controlled food challenges)
Number of subjects: 363
Study: 11008920

Group type: EXPERIMENTAL
Intervention: CYP1A1 I462V genotype
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: CYP1A1 I462V genotype with at least one valine allele
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: CYP1A1 I462V genotype with homozygous deletion of GSTM1
Number of subjects: 214

Group type: COMPARATOR
Intervention: Control group (no CYP1A1 I462V mutation)
Number of subjects: 214
Study: 9350363

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain (2 mg.kg‐1) - Wound infiltration (Group A)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain (2 mg.kg‐1) - Regional nerve blockade (Group B)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% plain (2 mg.kg‐1) - Combination of wound infiltration and regional nerve blockade (Group C)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 183
Study: 1491864

Group type: EXPERIMENTAL
Intervention: Topical 0.075% capsaicin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 23
Study: 3858479

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 33

Group type: COMPARATOR
Intervention: Corticosteroid (betamethasone)
Number of subjects: 33
Study: 31703146

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention (cognitive‐behavioral strategies, mindfulness, values‐based activity)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 85
Study: 30290765

Group type: EXPERIMENTAL
Intervention: Modified Robert Jones bandage (MRJB) compression therapy for 24 hours
Number of subjects: 90

Group type: COMPARATOR
Intervention: No compression therapy (Control)
Number of subjects: 90
Study: 27237764

Group type: EXPERIMENTAL
Intervention: mSMT treatment
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 16
Study: 24501162

Group type: EXPERIMENTAL
Intervention: 100 mg/day saffron
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: COMPARATOR
Intervention: No capsule (non-placebo control)
Number of subjects: 105
Study: 23430667

Group type: EXPERIMENTAL
Intervention: Water exercise session (40 minutes, moderately intense, predominantly aerobic)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control protocol (no exercise)
Number of subjects: 16
Study: 20004276

Group type: EXPERIMENTAL
Intervention: 1.0 mg intraamniotic (1.0 IA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1.0 mg intrafetal (1.0 IF)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1.5 mg intraamniotic (1.5 IA)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1.5 mg intrafetal (1.5 IF)
Number of subjects: 52